Bristol Myers ends $100M Phase 1 cancer ADC program
read at Endpoints ↗Negative
Bristol Myers Squibb announced it has discontinued development of its Phase 1 antibody-drug conjugate candidate BMS-986497/ORM-6151.
The decision follows a review of early clinical data, leading the company to halt the program that had cost roughly $100 million.
The termination was disclosed in a regulatory filing, and the company did not provide further details on the reasons or next steps.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Bristol Myers scraps $100M Orum-partnered cancer drug”
read at Endpoints ↗83 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that